Clinical Trials
27 trialsNCT01334073 2026-05-14
EVAX
University Hospital, Bordeaux
Phase 1 Completed
NCT04895748 2026-03-03
DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies
Novartis
Phase 1 Terminated
NCT07369505 2026-01-27
Sapu003 in Advanced mTOR-sensitive Solid Tumors
SAPU NANO (US) LLC
Phase 1 Recruiting
NCT03324373 2025-04-24
Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC)
University of Iowa
Phase 1 Completed
NCT00655655 2024-08-21
Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
Mayo Clinic
Phase 1 Completed
NCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT02106507 2023-05-26
ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT02890069 2023-01-11
A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat
Novartis
Phase 1 Completed
NCT02071862 2022-07-20
Study of the Glutaminase Inhibitor CB-839 in Solid Tumors
Calithera Biosciences, Inc
Phase 1 Completed
NCT01218555 2022-01-27
Study of Everolimus (RAD001) in Combination With Lenalidomide
Emory University
Phase 1 Completed
NCT02125084 2021-05-04
Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer
SCRI Development Innovations, LLC
Phase 1 Completed
NCT01152801 2020-12-21
Safety of RAD001 in Chinese Patients With Metastatic Renal Cell Cancer
Novartis
Phase 1 Completed
NCT01482156 2020-12-21
Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors
Novartis
Phase 1 Completed
NCT02077933 2020-12-08
Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors
Novartis
Phase 1 Completed
NCT01184326 2019-10-02
Expanded Phase I Pazopanib and Everolimus in Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer
Dana-Farber Cancer Institute
Phase 1 Completed
NCT02454478 2019-03-19
Study of Lenvatinib in Combination With Everolimus in Participants With Unresectable Advanced or Metastatic Renal Cell Carcinoma (RCC)
Eisai Inc.
Phase 1 Completed
NCT01115803 2019-02-05
A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors
Eli Lilly and Company
Phase 1 Terminated
NCT01548807 2018-08-22
Phase 1 Trial of the Mammalian Target of Rapamycin (mTOR) Inhibitor Everolimus Plus Radiation Therapy (RT) for Salvage Treatment of Biochemical Recurrence in Prostate Cancer Patients Following Prostatectomy
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
NCT01642732 2017-05-30
Study of Everolimus Added to Combined Hormonal and Radiation Therapy for High Risk Prostate Cancer
University of Michigan Rogel Cancer Center
Phase 1 Terminated
NCT00949949 2017-01-12
Everolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable Solid Tumors Refractory to Standard Therapy
Mayo Clinic
Phase 1 Completed
NCT00943956 2016-05-25
Everolimus, Bicalutamide, and Leuprolide Acetate in Treating Patients Undergoing Radiation Therapy For High-Risk Locally Advanced Prostate Cancer
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 1 Completed
NCT01182168 2016-03-31
Gemcitabine and Split-Dose Cisplatin Plus Everolimus (RAD001) in Patients With Advanced Solid Tumor Malignancies
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT00303732 2016-03-03
PTK/RAD
Duke University
Phase 1 Completed
NCT00788060 2015-02-16
Rad/Sutent
Duke University
Phase 1 Completed
NCT00384969 2014-08-18
Sorafenib and RAD001 Renal Cell Carcinoma
University of California, San Francisco
Phase 1 Completed
NCT01677390 2014-01-28
A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma
Seagen Inc.
Phase 1 Terminated
NCT00422344 2010-02-26
A Study of RAD001 and Sunitinib in Metastatic Renal Cell Carcinoma
Memorial Sloan Kettering Cancer Center
Phase 1 Completed